Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination
2024 · The Lancet Regional Health - Europe · 61 citations
https://doi.org/10.1016/j.lanepe.2023.100829
E
Edwin van Leeuwen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
109
Papers
1.6K
Citations
21
h-index
35
i10-index
Edwin van Leeuwen is an academic researcher from University of London. The author has contributed to research in topics: COVID-19 epidemiological studies & Influenza Virus Research Studies & Respiratory viral infections research. The author has an h-index of 21, co-authored 93 publications.
ORCID: 0000-0002-2383-5305Papers by this author
worksDeterminants of RSV epidemiology following suppression through pandemic contact restrictions
2022 · Epidemics · 49 citations
https://doi.org/10.1016/j.epidem.2022.100614
Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis
2022 · Vaccine · 21 citations
https://doi.org/10.1016/j.vaccine.2022.01.015
The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model
2022 · BMC Public Health · 11 citations
https://doi.org/10.1186/s12889-022-13219-4
Correction to “Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination” [The Lancet Regional Health – Europe 38 (2024) 100829]
2024 · The Lancet Regional Health - Europe · 0 citations
https://doi.org/10.1016/j.lanepe.2024.101073
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat